The DOI matches its Crossref record.
Evidence of CFTR Function in Cystic Fibrosis after Systemic Administration of 4-Phenylbutyrate
Open accessAbstract
Most individuals with cystic fibrosis (CF) carry one or two mutations that result in a maturation defect of the full-length protein. One such mutation, deltaF508, results in a mutant membrane glycoprotein that fails to progress to the apical membrane, where the wild-type protein normally functions as a cyclic AMP-regulated chloride channel. 4-Phenylbutyrate (Buphenyl), an orally bioavailable short chain fatty acid, modulates heat shock protein expression and restores maturation of the deltaF508 protein in vitro and in vivo. We performed a randomized, double-blind, placebo-controlled, dose-escalation and safety study of Buphenyl in 19 adults with CF (homozygous deltaF508) to test the hypothesis that Buphenyl would be safe, well-tolerated, and associated with an increase in chloride transport in nasal epithelia. Three dose levels (20, 30, or 40 g divided t.i.d.) of drug or placebo were given for 1 week. Serial measurements of chloride transport by nasal potential difference (NPD) testing and metabolic safety testing were performed. A maximum tolerated dose of 20 g was defined based on minimal adverse reactions, the safety profile, and a statistically significant induction of chloride transport that was maximal by day 3. This short-term phase I/II study demonstrates proof of principle that modulation of deltaF508 CFTR biosynthesis and trafficking is a viable therapeutic approach for cystic fibrosis.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
In and Out of the ER: Protein Folding, Quality Control, Degradation, and Related Human Diseases
Hebert, D. N., & Molinari, M. (2007) · Physiological Reviews · doi:10.1152/physrev.00050.2006 · Cited by 671
CFTR Modulators: The Changing Face of Cystic Fibrosis in the Era of Precision Medicine
Lopes-Pacheco, M. (2020) · Frontiers in Pharmacology · doi:10.3389/fphar.2019.01662 · Cited by 535
Archer, S. L., Weir, E. K., & Wilkins, M. R. (2010) · Circulation · doi:10.1161/circulationaha.108.847707 · Cited by 485
Chloride channels as drug targets
Verkman, A. S., & Galietta, L. J. V. (2009) · Nature Reviews Drug Discovery · doi:10.1038/nrd2780 · Cited by 469
Boyle, M. P., Bell, S. C., Konstan, M. W., McColley, S. A., Rowe, S. M., Rietschel, E., Huang, X., Waltz, D., Patel, N. R., & Rodman, D. (2014) · The Lancet Respiratory Medicine · doi:10.1016/s2213-2600(14)70132-8 · Cited by 452
Self-citationKerem, E., Hirawat, S., Armoni, S., Yaakov, Y., Shoseyov, D., Cohen, M., Nissim-Rafinia, M., Blau, H., Rivlin, J., Aviram, M., et al. (2008) · The Lancet · doi:10.1016/s0140-6736(08)61168-x · Cited by 403
CFTR: folding, misfolding and correcting the ΔF508 conformational defect
Lukacs, G. L., & Verkman, A. S. (2012) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2011.10.003 · Cited by 375
N-glycan structure dictates extension of protein folding or onset of disposal
Molinari, M. (2007) · Nature Chemical Biology · doi:10.1038/nchembio880 · Cited by 300
Linde, L., Boelz, S., Nissim-Rafinia, M., Oren, Y. S., Wilschanski, M., Yaacov, Y., Virgilis, D., Neu-Yilik, G., Kulozik, A. E., Kerem, E., et al. (2007) · Journal of Clinical Investigation · doi:10.1172/jci28523 · Cited by 300
Clinical and Experimental Applications of Sodium Phenylbutyrate
Iannitti, T., & Palmieri, B. (2011) · Drugs in R & D · doi:10.1007/bf03259725 · Cited by 270
The therapeutic potential of chemical chaperones in protein folding diseases
Cortez, L., & Sim, V. (2014) · Prion · doi:10.4161/pri.28938 · Cited by 254
Cystic fibrosis: a clinical view
Castellani, C., & Assael, B. M. (2017) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-016-2393-9 · Cited by 254
Second-Generation Pharmacological Chaperones: Beyond Inhibitors
Tran, M. L., Génisson, Y., Ballereau, S., & Dehoux, C. (2020) · Molecules · doi:10.3390/molecules25143145 · Cited by 63
Metadata
- Authors
- Zeitlin, P. L., Diener-West, M., Rubenstein, R. C., Boyle, M. P., Lee, C. K. K., & Brass-Ernst, L.
- Venue
- Molecular Therapy
- Publisher
- Elsevier BV
- Published
- 2002-07
- Volume
- 6
- Issue
- 1
- Pages
- 119-126
- ISSN
- 1525-0016 (ISSN-L)
- OpenAlex
- W2099049651
- Cited by
- 194
- References
- 0
- FWCI
- 9.91
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.